Introduction

MVC collaborates with US NIH to develop a single-shot live-attenuated dengue vaccine candidate which is expected to elicit thorough protection against all 4 distinct serotypes (DEN–1 to –4) of dengue viruses.

Dengue is caused by one of any of four related viruses. People who have had dengue in the past are more likely to develop severe dengue. Severe dengue can result in shock, internal bleeding, and even death.


Features

|Dengue Vaccine Development|

  1. Expected to be applicable to 2 to 59 year-old.
  2. Expected to be a single-shot vaccine with great protection.
  3. Expected to provide thorough protection against all 4 subtypes of dengue virus, type I to type IV.
     

Progress

  • MVC has completed the phase II "Proof-of-Concept" (POC) clinical trial.
  • The result of the study demonstrates the dengue vaccine has a favorable safety profile. The vaccinated group generated higher neutralizing antibodies against all 4 subtypes of dengue virus compared to the placebo group.

Dengue Vaccine

R&D/Preclinical Phase I Phase II Phase III Marketed


We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.
Agree